The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans
| Autor: | Sandström, Rikard, Knutson, Tina W, Knutson, Lars, Jansson, Britt, Lennernäs, Hans |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Antifungal Agents Oxidoreductases N-Demethylating Stereoisomerism Calcium Channel Blockers Perfusion Jejunum Ketoconazole Cytochrome P-450 Enzyme System Intestinal Absorption Verapamil Cytochrome P-450 CYP3A Humans Drug Interactions Female Aryl Hydrocarbon Hydroxylases Infusions Intravenous Algorithms Chromatography High Pressure Liquid |
| Popis: | The purpose of this human intestinal perfusion study was to investigate the effect of ketoconazole on the jejunal permeability and first-pass metabolism of (R)- and (S)-verapamil in humans.A regional single-pass perfusion of the jejunum was performed using a Loc-I-Gut(R) perfusion tube in six healthy volunteers. Each perfusion lasted for 200 min and was divided into two periods of 100 min each. The inlet concentration of (R/S)-verapamil was 120 mg l-1 in both periods, and ketoconazole was added at 40 mg l-1 in period 2. (R/S)-verapamil was also administered as a short intravenous infusion of 5 mg, over a period of 10 min. The appearance ratios of the CYP3A formed metabolites (R)- and (S)-norverapamil were also estimated in the outlet jejunal perfusate.The effective jejunal permeability (Peff) of both (R)- and (S)-verapamil was unaffected by the addition of ketoconazole in period 2 suggesting that ketoconazole had no effect on the P-glycoprotein mediated efflux. However, the appearance ratio of both (R)- and (S)-norverapamil in the outlet jejunal perfusate decreased in the presence of ketoconazole. The rate of absorption into plasma of (R)- and (S)-verapamil increased despite the low dose of ketoconazole added, indicating an inhibition of the gut wall metabolism of (R/S)-verapamil by ketoconazole.Ketoconazole did not affect the jejunal Peff of (R/S)-verapamil, but it did increase the overall transport into the systemic circulation (bioavailability), probably by inhibition of the gut wall metabolism of verapamil. This might be due to ketoconazole being less potent as an inhibitor of P-glycoprotein than of CYP3A4 in vivo in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|